Compositions and methods for treating or preventing Hepadnaviridae infection
AssigneeMigenix Inc.
InventorDominique Dugourd
Life of this patent
Estimating the term…
Abstract
The present disclosure relates generally to the use of certain castanospermine esters to treat or prevent infections caused by Hepadnaviridae, particularly infections caused by hepatitis B virus (HBV), and to the use of such compounds to examine the biological mechanisms of HBV infection.
Claims70
A method of treating or preventing a Hepadnaviridae infection, comprising administering to a subject a glucosidase inhibitor or pharmaceutically acceptable salts thereof, wherein the glucosidase inhibitor has the following structural formula (I):
- wherein R, R1 and R2 are independently hydrogen, C1-14 alkanoyl, C2-14 alkenoyl, cyclohexanecarbonyl, C1-8 alkoxyacetyl,
- naphthalenecarbonyl optionally substituted with a methyl or halogen;
- phenyl(C2-6 alkanoyl), wherein the phenyl is optionally substituted with a methyl or halogen;
- cinnamoyl;
- pyridinecarbonyl optionally substituted with a methyl or halogen;
- dihydropyridine carbonyl optionally substituted with a C1-10 alkyl;
- thiophenecarbonyl optionally substituted with methyl or halogen;
- or furancarbonyl optionally substituted by a methyl or halogen;
- Y is hydrogen, C1-4 alkyl, C1-4 alkoxy, halogen, trifluoromethyl, C1-4 alkylsulfonyl, C1-4 alkylmercapto, cyano or dimethylamino;
- Y′ is hydrogen, C1-4 alkyl, C1-4 alkoxy, halogen or it is combined with Y to give 3,4-methylenedioxy;
- Y″ is hydrogen, C1-4 alkyl, C1-4 alkoxy or halogen;
- and
- wherein at least one, but not more than two, of R, R1 and R2 is hydrogen:
A method for treating or preventing a Hepadnaviridae infection, comprising administering to a subject a combination of an agent that alters immune function, and a glucosidase inhibitor and pharmaceutically acceptable salts thereof, wherein the glucosidase inhibitor has a structure according to formula (I):
- wherein R, R1 and R2 are independently selected from hydrogen, C1-14 alkanoyl, C2-14 alkenoyl, cyclohexanecarbonyl, C1-8 alkoxyacetyl,
- naphthalenecarbonyl optionally substituted with a methyl or halogen;
- phenyl(C2-6 alkanoyl), wherein the phenyl is optionally substituted with a methyl or halogen;
- cinnamoyl;
- pyridinecarbonyl optionally substituted with a methyl or halogen;
- dihydropyridine carbonyl optionally substituted with a C1-10 alkyl;
- thiophenecarbonyl optionally substituted with methyl or halogen;
- or furancarbonyl optionally substituted by a methyl or halogen;
- Y is hydrogen, C1-4 alkyl, C1-4 alkoxy, halogen, trifluoromethyl, C1-4 alkylsulfonyl, C1-4 alkylmercapto, cyano or dimethylamino;
- Y′ is hydrogen, C1-4 alkyl, C1-4 alkoxy, halogen or it is combined with Y to give 3,4-methylenedioxy;
- Y″ is hydrogen, C1-4 alkyl, C1-4 alkoxy or halogen;
- and
- wherein at least one, but not more than two, of R, R1 and R2 is hydrogen.
A method for treating a Hepadnaviridae infection, comprising administering to a subject an agent that alters viral replication, and a glucosidase inhibitor and pharmaceutically acceptable salts thereof, wherein the glucosidase inhibitor has a structure according to formula (I):
- wherein R, R1 and R2 are independently selected from hydrogen, C1-14 alkanoyl, C2-14 alkenoyl, cyclohexanecarbonyl, C1-8 alkoxyacetyl,
- naphthalenecarbonyl optionally substituted with a methyl or halogen;
- phenyl(C2-6 alkanoyl), wherein the phenyl is optionally substituted with a methyl or halogen;
- cinnamoyl;
- pyridinecarbonyl optionally substituted with a methyl or halogen;
- dihydropyridine carbonyl optionally substituted with a C1-10 alkyl;
- thiophenecarbonyl optionally substituted with methyl or halogen;
- or furancarbonyl optionally substituted by a methyl or halogen;
- Y is hydrogen, C1-4 alkyl, C1-4 alkoxy, halogen, trifluoromethyl, C1-4 alkylsulfonyl, C1-4 alkylmercapto, cyano or dimethylamino;
- Y′ is hydrogen, C1-4 alkyl, C1-4 alkoxy, halogen or it is combined with Y to give 3,4-methylenedioxy;
- Y″ is hydrogen, C1-4 alkyl, C1-4 alkoxy or halogen;
- wherein at least one, but not more than two, of R, R1 and R2 is hydrogen.
Dependencies are inferred from the claim text.